**DANGER**
**KEEP OUT OF REACH OF CHILDREN**
**FOR ANIMAL TREATMENT ONLY**
**RESTRICTED VETERINARY MEDICINE**

# Carprieve 20 mg Tablets
# Carprieve 50 mg Tablets
# Carprieve 100 mg Tablets

**READ THE ENTIRE LABEL BEFORE USE**

**PRESENTATION:**
Carprieve 20 mg and 50 mg Tablets are white or off white circular tablets, Carprieve 100 mg Tablets are yellow circular tablets, imprinted with their milligram content. Tablets contain either CARPROFEN 20mg or CARPROFEN 50mg or CARPROFEN 100mg.
**Carprieve 20 mg Tablets** are provided in packs of 100; **Carprieve 50 mg Tablets** are provided in packs of 100 or 500; **Carprieve 100 mg Tablets** are provided either in tubs of 14, 30 and 100 tablets; or in blister packs with 10 tablets per blister. Available blister pack sizes range from 10 to 1000 tablets.

**INDICATIONS:**
Carprieve Tablets are a non-steroidal anti-inflammatory formulation with analgesic action. They are indicated for analgesia and reduction of inflammation, for example in degenerative joint disease of the dog.

**DOSAGE & ADMINISTRATION:**
For oral administration.
An initial dose of 2-4 mg/kg bodyweight / day is recommended to be given in 2 equally divided doses. This is provided by one ***Carprieve 20 mg Tablet*** per 20 to 10 kg bodyweight, each morning and night; or by one ***Carprieve 50 mg Tablet*** per 50 to 25 kg bodyweight, each morning and night; ***or*** by one ***Carprieve 100 mg Tablet*** per 100 to 50 kg bodyweight, each morning and night.
After 7 days dose may be reduced to 2 mg/kg/day as a single daily dose, subject to clinical response. Duration of treatment will depend on the response seen. Long-term treatment should be under regular veterinary supervision.

**CONTRAINDICATIONS:**
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Toxic effects can occur when drugs that are highly bound to plasma proteins (such as NSAIDs) compete with other highly bound drugs, leading to excess free drug(s) in plasma.
Do not use where there is a possibility of gastro-intestinal ulceration or bleeding; in animals suffering from cardiac, hepatic or renal disease; or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Use in animals less than 6 weeks of age or in aged animals may involve additional risk. If prescribed in such cases, animals may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potential nephrotoxic drugs should be avoided.
Do not exceed the stated dose or the duration of treatment.
No specific studies have been reported in pregnant dogs.
NSAIDs can inhibit phagocytosis; thus appropriate antimicrobial therapy should be given concurrently in the treatment of inflammatory conditions associated with bacterial infection.

**Further information:**
Experimental and clinical evidence suggests that gastro-intestinal tract ulceration is rare with use of carprofen in the dog, and only occurs at dosages well above the therapeutic dose.

**WARNING**
**Dangerous to the Environment**
**Handling Precautions:**
Carprofen may be dangerous if swallowed and may possibly affect gastrointestinal tract.
Wash hands and exposed skin before meals and after use.
Toxic to terrestrial vertebrates. Avoid release to the environment.
**First Aid:**
If swallowed do NOT induce vomiting. For advice contact the National Poisons Centre, phone 0800 POISON (0800 764 766) or a doctor immediately.
**Disposal:**
Preferably dispose of product by use. Dispose of product and packaging at an approved landfill or equivalent facility.

Store below 30 °C, in a dry place out of direct sunlight.

Carprieve 20 mg Tablets registered pursuant to the ACVM Act 1997 No. A9026
Carprieve 50 mg Tablets registered pursuant to the ACVM Act 1997 No. A9025
Carprieve 100 mg Tablets registered pursuant to the ACVM Act 1997 No. A10193

See www.foodsafety.govt.nz for registration conditions.

Registered to & distributed by:
Norbrook NZ Ltd
KPMG Centre, 18 Viaduct Harbour Avenue
Auckland
Ph: 0800 224 022

Manufactured by:
Norbrook Laboratories Ltd.
Station Works, NEWRY,
Co. Down, Northern Ireland.

009460I09

Norbrook®